Shares of Guardian Pharmacy Services, Inc. (NYSE:GRDN – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the ten research firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year target price among analysts that have covered the stock in the last year is $45.5714.
GRDN has been the topic of a number of recent analyst reports. Truist Financial lifted their target price on Guardian Pharmacy Services from $47.00 to $51.00 and gave the company a “buy” rating in a research report on Monday. KeyCorp initiated coverage on shares of Guardian Pharmacy Services in a research note on Tuesday. They issued an “overweight” rating and a $52.00 price target on the stock. Oppenheimer lifted their price target on shares of Guardian Pharmacy Services from $43.00 to $49.00 and gave the company an “outperform” rating in a report on Friday, August 7th. Weiss Ratings upgraded shares of Guardian Pharmacy Services from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, August 20th. Finally, Bank of America increased their price objective on shares of Guardian Pharmacy Services from $42.00 to $47.00 and gave the company a “buy” rating in a research note on Wednesday, June 17th.
Read Our Latest Research Report on GRDN
Institutional Inflows and Outflows
Guardian Pharmacy Services Stock Performance
NYSE GRDN opened at $43.20 on Monday. The stock has a 50 day moving average price of $40.72 and a 200-day moving average price of $39.12. Guardian Pharmacy Services has a one year low of $23.14 and a one year high of $48.33. The company has a market capitalization of $2.15 billion, a P/E ratio of 41.94, a P/E/G ratio of 2.31 and a beta of 0.06.
Guardian Pharmacy Services (NYSE:GRDN – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.03. Guardian Pharmacy Services had a return on equity of 29.97% and a net margin of 4.50%.The company had revenue of $351.77 million for the quarter, compared to analyst estimates of $340.45 million. As a group, equities analysts predict that Guardian Pharmacy Services will post 1.19 EPS for the current fiscal year.
About Guardian Pharmacy Services
Guardian Pharmacy Services, Inc is a long-term care pharmacy company that provides prescription medications and related pharmacy services to residents of assisted living communities, skilled nursing facilities, memory care centers and other institutional care settings.
The company’s services include medication dispensing and packaging, prescription delivery, medication management, pharmacy consulting and clinical support. Guardian works with care providers, residents and their families to help coordinate medication regimens, improve adherence and support the ongoing pharmacy needs of patients who may require complex or recurring treatments.
Guardian Pharmacy Services operates through a network of community-based pharmacies serving long-term care customers in multiple U.S.
Featured Articles
- Five stocks we like better than Guardian Pharmacy Services
- Chips to Bots: Qualcomm’s Agentic AI Breakout
- Ciena Fell 40%—Now One Analyst Sees 50% Upside
- Energy Transfer Taps the AI Power Boom
- Viking’s Obesity Edge May Be Staying Power, Not Weight Loss
Receive News & Ratings for Guardian Pharmacy Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardian Pharmacy Services and related companies with MarketBeat.com's FREE daily email newsletter.
